PFE ends deal with SGMO for hemophilia A gene therapy candidate. NVS' gene therapy for SMA meets goal in study.

Jefferies analyst Maury Raycroft lowered the firm’s price target on Sangamo (SGMO) to $3 from $7 and keeps a Buy rating on the shares after the ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, ...

Sangamo (SGMO) announced it will regain development and commercialization rights to giroctocogene fitelparvovec, an investigational gene ...

Novartis’ NVS phase III study showed a positive risk-benefit profile of an investigational gene therapy candidate, intrathecal onasemnogene abeparvovec (OAV101 IT), for treating spinal muscular ...

Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner Pfizer (PFE) decided not to proceed with further development of a new gene therapy to treat ...

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

After years of almost constant struggle, one crisis after another, the financial markets finally got some respite in 2024.

Pfizer PFE is a prominent member of the group ... application with the US Food and Drug Administration and remain on file for the life of the product. This means West often remains the primary ...